Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and Sintilimab in Advanced Gastric Cancer
NCT04089657Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of Rivoceranib, sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
Rivoceranibsintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04089657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089657.